Chen Cheng, Pham Nguyen Thanh Phuong, Hughes John E, Hennessy Sean, Leonard Charles E, Miano Todd A, Douros Antonios, Gagne Joshua J, Bykov Katsiaryna
Division of Epidemiology II, Office of Surveillance and Epidemiology, United States Food and Drug Administration, Silver Spring, Maryland, USA.
Department of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Pharmacoepidemiol Drug Saf. 2025 Jan;34(1):e70088. doi: 10.1002/pds.70088.
Drug-drug interactions (DDIs) represent a significant concern for clinical care and public health, but the health consequences of many DDIs remain largely underexplored. This knowledge gap underscores the critical need for pharmacoepidemiologic research to evaluate real-world health outcomes of DDIs. In this review, we summarize the definitions commonly used in pharmacoepidemiologic DDI studies, discuss common sources of bias, and illustrate through examples how these biases can be mitigated.
药物相互作用（DDIs）是临床护理和公共卫生的重大关注点，但许多药物相互作用对健康的影响在很大程度上仍未得到充分探索。这一知识空白凸显了药物流行病学研究评估药物相互作用实际健康结果的迫切需求。在本综述中，我们总结了药物流行病学药物相互作用研究中常用的定义，讨论了常见的偏倚来源，并通过实例说明如何减轻这些偏倚。
